124 results about "Glycoconjugate" patented technology

The invention discloses a method for preparing multi-branch oligosaccharide. According to the method, an in-vitro enzymatic synthesis strategy is adopted, monosaccharide activation and glycosyl transferase catalytic reaction are coupled, operation is simple and safe, the reaction conversion rate and the product yield are greatly improved, and a foundation is laid for industrial production of multi-branched oligosaccharides, especially multi-branched human milk oligosaccharides. According to the invention, synthesis of human milk oligosaccharides with three-branch, four-branch and other multi-branch structures can be realized, and reference is provided for synthesis of oligosaccharides and glycoconjugates with more complex structures.

The present invention provides methods for glycosylation and compound preparation. The compounds include galactosylated, sialylated, fucosylated, and N-acetylglucosaminated compounds from simple oligosaccharides and sugars of animal, plant, or microbial origin. In certain embodiments, the invention provides for trinucleotide-free enzymatic production of oligosaccharides starting from simple sugars, including plant-based sugars. The present invention also provides methods of enzymatic production of fucosylated oligosaccharides and fucosylated antibody-glycan conjugates from ordinary enzymes. The production may be a cell-free, one-pot synthesis using an enzyme and, in some embodiments, an immobilized enzyme. The synthesis is a highly customizable and efficient cell-free manufacturing process. In some embodiments, lactose derivatives and human milk oligosaccharides (HMOs) are produced.

To provide a novel mutant form of α-fucosidase (α-L-fucosidase), which exhibits enhanced α-(1,6) fucosidase activity.SOLUTION: The present disclosure relates to compositions comprising the novel mutant form of α-fucosidase, and methods of using the novel mutant form of α-fucosidase to cleave α-(1,6)-linked fucoses in the glycoconjugates. In one embodiment, the present disclosure provides a mutant form of α-L-fucosidase for the improved enzymatic hydrolysis of fucose in vitro.SELECTED DRAWING: None

The present invention relates to sulforaphane glycoconjugate compounds, as well as to the synthesis and therapeutic uses thereof for treating inflammatory diseases.

The present disclosure provides methods, compositions, and kits for the rapid release, labeling, and detection of O-glycans present on a glycoconjugate, such as a glycoprotein, glycopeptide, peptidoglycan, or proteoglycan of interest. The compositions and methods allow the released O-glycans to be subjected to high-throughput analysis.

The disclosure discloses a chemical synthesis method and an application of V. cholerae serotype O100 O-antigen oligosaccharides, belonging to the field of chemical technologies. The disclosure uses three monosaccharide building blocks and five carboxylic acid derivatives to synthesize five oligosaccharide fragments of V. cholerae serotype O100 O-antigen under the action of the solvent effect, temperature effect, neighboring group participation effect, etc., through orthogonal protection, selective assembly and amide coupling. The absolute configurations and immunological effects of 3,5-dihydroxyhexanoyl in the O-antigen trisaccharide are illustrated by the synthesized oligosaccharide fragments in combination with the NMR analysis and glycan microarray technology, thereby providing a theoretical basis for further structure-activity study and minimal antigenic epitope screening. The disclosure has excellent application prospects in the aspects of development of V. cholerae synthetic glycoconjugate vaccines and new drugs, etc.

The present invention relates to a method for producing cytidine 5′-monophospho-N-acetyl-neuraminic acid (CMP-Neu5Ac, 1) from low-cost substrates N-acetyl-D-glucosamine (GlcNAc), pyruvate, cytidine and polyphosphate in a single reaction mixture with a set of optionally immobilized or optionally co-immobilized enzymes comprising N-acylglucosamine 2-epimerase (AGE), an N-acetylneuraminate lyase (NAL), an N-acylneuraminate cytidylyltransferase (CSS), a uridine kinase (UDK), a uridine monophosphate kinase and a polyphosphate kinase 3 (PPK3). Further, said process may be adapted to produce Neu5Acylated i.e. sialylated biomolecules and biomolecules including a saccharide, a peptide, a protein, a glycopeptide, a glycoprotein, a glycolipid, a glycan, an antibody, and a glycoconjugate, in particular, an antibody drug conjugate, and a carbohydrate conjugate vaccine, or a flavonoid.

The present disclosure provides a combination comprising an antibody that specifically binds to C5 and a C5 iRNA, which is a glycoconjugate containing a ligand with a terminal N-acetylgalactosamine (GalNAc) residue and / or N-acetylglucosamine (GlcNAc) residue. A method for reducing degradation of glycoconjugate RNA by the beta-hexosaminidase enzyme is also provided. The present disclosure also includes a method for treating or preventing a C5-related disease or disorder by administering one or more doses of an anti-C5 antibody or antigen-binding fragment thereof in combination with one or more doses of a C5 iRNA; preferably, the anti-C5 antibody or fragment and the C5 iRNA are in a combination. The present disclosure also includes a dosing regimen for treating a C5-related disease or disorder with a combination of an anti-C5 antibody and a C5 iRNA in either a treatment-naive subject or a subject switching from a previous C5 inhibitor therapy.

To provide immunogenic compositions capable of providing appropriate protection against Streptococcus pneumoniae serotypes not found in conventional vaccines.SOLUTION: The present invention provides new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR, SYNFLORIX and / or PREVNAR 13. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using the novel immunogenic compositions.SELECTED DRAWING: Figure 1

The invention belongs to the technical field of organic synthesis, and particularly relates to a synthesis method of a Baliella chensinensis lipopolysaccharide O-antigen and application of the Baliella chensinensis lipopolysaccharide O-antigen in the aspect of immunocompetence. The raw materials such as monosaccharide, disaccharide, trisaccharide, tetrasaccharide and the like for preparing the glycoconjugate vaccine can be efficiently synthesized, and the synthesis selectivity and the synthesis efficiency are improved. According to the invention, unprotected ammonia is selected to construct uronic acid amide, and hydrogenation is successfully carried out through the method to obtain the target molecular trisaccharide. Subsequently, monosaccharide, disaccharide and tetrasaccharide target molecules are constructed. Wherein in the construction process of the tetrasaccharide, a method of combining TEMPO and NaOCl is adopted to oxidize the tetrasaccharide into aldehyde, then Pinnick is adopted to oxidize the aldehyde into carboxylic acid, and a two-step one-pot method is adopted to construct the tetrasaccharide. According to the invention, glycoconjugate is prepared by conjugation with HSA, and the glycoconjugate lays a raw material foundation for research and development of the Babyte's fermentum lipopolysaccharide vaccine.

The present invention relates to a large scale GMP synthesis method of a modified glucan conjugate, and more particularly, to a glucan-guanidine-bisphosphonate conjugate wherein the bisphosphonate is an alendronate group. The large-scale GMP synthesis method related to the invention can be used for producing the glucan-guanidine-bisphosphonate conjugate with high purity and medicinal grade. The invention also relates to an application of the glucan-guanidine-bisphosphonate conjugate in a medicine for treating tumors.

The invention discloses a method for preparing a multi-branch O-GalNAc (O-GalNAc) oligosaccharide. According to the method, an in-vitro enzymatic synthesis strategy is adopted, monosaccharide activation and glycosyl transferase catalytic reaction are coupled, operation is simple and safe, the reaction conversion rate and the product yield are greatly improved, and a foundation is laid for industrial production of O-GalNAc oligosaccharide. According to the invention, synthesis of O-GalNAc oligosaccharides with multi-branch structures such as three branches, four branches and the like can be realized, and reference is provided for synthesis of oligosaccharides and glycoconjugates with more complex structures.

The application relates to the field of food preservation, in particular to a natural bacteriostatic material and a preparation method and application thereof, and a preparation method of the natural bacteriostatic material, which comprises the following steps: mixing natural gelatin and dextran with deionized water, stirring, and freeze-drying to obtain a gelatin-dextran mixture powder, wherein the mass ratio of the natural gelatin to the dextran is 1-2:1-4, and the molecular weight of the dextran is 150-200 kDa; performing a glycosylation reaction on the gelatin-dextran mixture powder to obtain a gelatin-dextran conjugate; dissolving the gelatin-dextran conjugate in a buffer solution to obtain an emulsifier; and homogenizing edible essential oil, the emulsifier and deionized water, and performing ultrasonic emulsification to obtain the natural bacteriostatic material. The preparation method is simple, the conditions are simple, the prepared natural bacteriostatic material has good stability, and the shelf life of food can be prolonged.

This invention concerns a covalent conjugate comprising a glycan being covalently linked through a pyrophosphate (PP) linker to a lipid carrier molecule which is phytol, as well as a cell-free in vitro method and a cell free in vitro system for forming of a glycosylated peptide or polypeptide using said conjugate. The invention further concerns an enzymatic synthesis system for the formation of a glycan-conjugate of this invention. The invention further concerns a peptide or polypeptide with a glycosyl-moiety acceptor residue having an exogenous N-linked glycosylation sequence X1X2NYT, wherein X1 is any one of alanine (A), valine (V), leucine (L), isoleucine (I), proline (P), phenylalanine (F), cysteine (C), tryptophan (W) and methionine (M), and wherein X2 is either alanine (A) or valine (V), as well as an N-glycosylated conjugate of said peptide or polypeptide.

The present invention relates to a method for producing α-sialyl-β-D-galactoside saccharides, particularly α-sialyl-(2→3)-β-D-galactoside saccharides and α-sialyl-(2→6)-β-D-galactoside saccharides, from a β-D-galactoside saccharide, a sialic acid donor, and an enzyme with β-galactoside α-sialyltransferase activity. The enzymes with β-galactoside α-sialyltransferase activity used herein do not exhibit catalytic activity towards the hydrolysis of cytidine 5'-monophospho-N-acetyl-neuraminic acid to cytidine and N-acetyl-neuraminic acid. The method can be performed in vitro and in vivo using a genetically engineered cell comprising a nucleic acid encoding said enzyme. Further, said process may be adapted to produce the sialic acid donor CMP-Neu5Ac from low-cost substrates N-acetyl-D-glucosamine (GlcNAc), pyruvate, a cytidine phosphate (CMP, CDP or CTP) and polyphosphate in a single reaction mixture with a set of optionally immobilized or optionally co-immobilized enzymes comprising N-acylglucoamine 2-epimerase (AGE), an N-acetylneuraminate lyase (NAL), an N-acylneuraminate cytidylyltransferase (CSS), optional a uridine kinase (UDK), a uridine monophosphate kinase and a polyphosphate kinase 3 (PPK3).

The present teachings relate to methods, systems, and kits for the preparation, purification and / or analysis of a glycan or glycoconjugate, and specifically to a magnetic bead based sample preparation protocol. In some aspects, the sample preparation protocol can provide for glycoconjugate capture, glycan release, fluorescent derivatization, and glycan purification for subsequent capillary electrophoresis, liquid chromatography, or other glycoanalytical method using magnetic beads containing negatively charged carboxyl groups extending from the surface of the magnetic beads.

The present invention belongs to the field of composite materials technology, specifically relating to an edible mycorrhizal glycoconjugate-graphene conductive film and its preparation method. This invention uses chitosan-glucan complex (CGC), a root glycoconjugate extracted from the mycorrhizae of Flammulina velutipes, as raw material. Extracting CGC from the mycorrhizae requires only mild acid and alkali treatment to remove components such as proteins, minerals, and lipids, while also minimizing damage to the CGC and improving its purity. The prepared CGC, when used as a dispersant, improves graphene agglomeration. Compared to graphene without CGC, at the optimal concentration of CGC added, the median particle size decreased by 43.11%, and the absolute value of the zeta potential increased by 160.07%. The addition of CGC to graphene significantly enhances its dispersibility, improving the tensile strength and conductivity of the CGC-graphene film.

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. The immunogenic compositions of the invention typically comprise at least one glycoconjugate derived from a Streptococcus pneumoniae serotype not found in Prevnar, Synflorix, and / or Prevnar 13. The present invention also relates to the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection using said novel immunogenic compositions.

A method of making a chitosan conjugate, the method comprising: contacting chitosan, a dicarboxylic acid, and 4-(4, 6-dimethoxy-1, 3, 5-triazin-2-yl)-4-methyl-morpholinium chloride (DMTMM) in an aqueous solvent, thereby forming a reaction mixture comprising a chitosan conjugate wherein the chitosan conjugate comprises a repeating unit of formula I, or a conjugate salt thereof, wherein R1 is-(C = O) (CH2) mCO2H; and m is an integer selected from 1 to 12.

The invention discloses 2-phenethyl alcohol-beta-D-glucoside catalyzed and synthesized by a cofactor self-circulating multi-enzyme cascade system and application of the 2-phenethyl alcohol-beta-D-glucoside. The system comprises phenylalanine dehydrogenase and a mutant thereof, wherein the phenylalanine dehydrogenase is used for converting L-phenylalanine (L-Phe) into phenylpyruvic acid (PPA); pPA is converted into pyruvate decarboxylase (Aro10) of phenylacetaldehyde; the alcohol dehydrogenase is used for reducing phenylacetaldehyde into 2-phenethyl alcohol (2-PE) or a mutant of the alcohol dehydrogenase; 2-PE is converted into sucrose synthase (SuSy) of 2-phenethyl alcohol-beta-D-glucoside (2PE-Glc) or a mutant of the sucrose synthase, and UDP-glucosyltransferase (UGT) or a mutant of the UDP-glucosyltransferase. A novel multi-enzyme cascade system with cofactor self-circulation capability is realized and is used for efficiently synthesizing 2PE-Glc from L-phenylalanine. The invention not only provides an effective 2PE-Glc biosynthesis strategy, but also shows the potential of a multi-enzyme cascade system in the aspect of synthesizing biologically active complex glycoconjugates.

The present disclosure provides methods and compositions for modulating cell surface proteins and receptor complexes using a novel class of glycan conjugates that can be used to engage the signaling pathways within desired cell types. Such defined cell-targeting bioactive glyco-ligands are directed for cell engagement and activation in therapeutic applications.

The present invention relates to a novel vaccine formulation comprising a conjugated Streptococcus pneumoniae capsular saccharide antigen (glycoconjugate), and to the use thereof. The present invention relates to a novel vaccine formulation comprising a conjugated Streptococcus pneumoniae capsular saccharide antigen (glycoconjugate). The vaccine formulations of the present invention would typically include at least one glycoconjugate from Streptococcus pneumoniae serotype in a formulation designed to promote resuspension.

This invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular glycoantigens (glycoconjugates) and their uses. The immunogenic compositions of this invention will generally comprise at least one glycoconjugate derived from a Streptococcus pneumoniae serotype not found in Prevnar, Synflorix, and / or Prevnar 13. This invention also relates to the use of said novel immunogenic compositions for the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection.

The present invention relates to immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof. In particular, the present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. The immunogenic compositions of the present invention will generally comprise at least one glycoconjugate from Streptococcus pneumoniae serotypes, wherein the Streptococcus pneumoniae serotypes are not found in Prevnar, Synflorix, and / or Prevnar 13. The invention also relates to vaccination of human subjects, in particular infants and elderly people, against pneumococcal infections using the novel immunogenic compositions.

The present disclosure generally relates to improved methods for preparing glycoconjugates. The method includes conjugating a saccharide to a carrier protein using an acetoxyborohydride-containing reducing mixture prepared in situ.

Disclosed are a chemical synthesis method for Vibrio cholerae serotype O100 O-antigen oligosaccharide, and a use, belonging to the technical field of chemistry. The present invention uses three monosaccharide building blocks and five kinds of carboxylic acid derivative, and under the effects of solvent, temperature and neighboring group participation, through orthogonal protection, selective assembly and amide coupling, five Vibrio cholerae serotype O100 O-antigen oligosaccharide fragments are synthesized. Using the synthesized oligosaccharide fragments, combined with NMR analysis and carbohydrate chip technology, the absolute configuration and immunological function of the 3,5-dihydroxyhexanoyl group in the O-antigen trisaccharide are clarified, providing a theoretical basis for further structure-activity research and minimal antigen epitope screening. The present invention has promising applications in the synthesis of Vibrio cholerae glycoconjugate vaccines and the development of new drugs.

The present invention relates to fermentation methods for incorporating azido groups in bacterial capsular polysaccharides. The invention also relates to capsular polysaccharides comprising azido groups obtained by said methods. The capsular polysaccharides comprising azido groups may be used for click-based conjugation with alkyne-labeled carrier to generate glycoconjugates. The polysaccharides and glycoconjugates obtained by the method may be further used for preparation of immunogenic compositions for preventing and treating infections caused by the organism.

A tetrasaccharide of formula I and a method of production thereof are provided. Furthermore, a conjugate comprising the tetrasaccharide and a molecule attached to the tetrasaccharide, preferably via its amine group, is also provided. Compositions, preferably immunogenic or vaccine compositions, comprising this tetrasaccharide or this conjugate are also provided. Such tetrasaccharides, conjugates, and compositions can be used for preventing or treating a disease caused by a Burkholderia infection in a subject, for inducing the production of anti-Burkholderia antibodies in a subject, or for diagnosing a Burkholderia infection in a subject. Preferably, the Burkholderia infection is an infection by Burkholderia pseudomallei (Bp) or Burkholderiamallei (Bm); the disease is melioidosis or glander; and / or the anti-Burkholderia antibodies are anti-Burkholderia pseudomallei(Bp) antibodies or anti-Burkholderia mallei (Bm) antibodies.

Among its various embodiments, the disclosure provides improved methods for producing glycoconjugates of carrier protein, including CRM197, and bacterial capsular saccharide, including those isolated from various Streptococcus pneumoniae serotypes.